AVXL — Anavex Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00- $359.18m
- $256.60m
- 30
- 19
- 18
- 10
Annual balance sheet for Anavex Life Sciences, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | 2025 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 152 | 149 | 151 | 132 | 103 |
| Net Total Receivables | 9.14 | 3.19 | 2.71 | 2.45 | 0.809 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 162 | 153 | 154 | 136 | 104 |
| Total Assets | 162 | 153 | 154 | 136 | 104 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10.8 | 10.2 | 12.5 | 15.3 | 8.95 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 10.8 | 10.2 | 12.5 | 15.3 | 8.95 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 151 | 142 | 142 | 120 | 94.9 |
| Total Liabilities & Shareholders' Equity | 162 | 153 | 154 | 136 | 104 |
| Total Common Shares Outstanding |